Kamada (NASDAQ:KMDA) Share Price Passes Below Two Hundred Day Moving Average of $5.46

Kamada Ltd. (NASDAQ:KMDA) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.46 and traded as low as $5.06. Kamada shares last traded at $5.10, with a volume of 7,991 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on KMDA shares. StockNews.com raised shares of Kamada from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Thursday, March 7th.

Kamada Stock Performance

The stock’s 50 day moving average price is $5.74 and its 200 day moving average price is $5.46. The company has a market capitalization of $293.10 million, a P/E ratio of 34.00 and a beta of 1.04.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.04. Kamada had a net margin of 5.81% and a return on equity of 5.66%. The company had revenue of $36.43 million for the quarter, compared to analyst estimates of $37.71 million. On average, analysts expect that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. EWA LLC acquired a new position in Kamada during the fourth quarter worth $68,000. Y.D. More Investments Ltd acquired a new position in Kamada during the third quarter worth $75,000. Calton & Associates Inc. acquired a new position in Kamada during the fourth quarter worth $111,000. Aristides Capital LLC raised its holdings in Kamada by 41.6% during the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares during the last quarter. Finally, Meitav Investment House Ltd. raised its holdings in Kamada by 17.2% during the third quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company’s stock worth $412,000 after buying an additional 11,284 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.